Hopstem Biotech

News

China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.